Insulin-like growth factor-1 fails to enhance central nervous system myelin repair during autoimmune demyelination

B. Cannella, D. Pitt, E. Capello, C. S. Raine

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Previous studies have shown that insulin-like growth factor-1 (IGF-1) has beneficial effects, both clinically and histopathologically, on experimental autoimmune encephalomyelitis (EAE), although results vary depending on species and treatment regimen. The present study investigated whether IGF-1, delivered at different time points during the acute and chronic phases of adoptively transferred EAE in SJL mice, had the ability to affect or enhance myelin regeneration. Central nervous system tissue sampled at different stages of treatment was subjected to detailed neuropathological, immunocytochemical and molecular analysis. The results revealed some transient clinical amelioration and low level remyelination after IGF-1 administration during the acute phase of EAE. However, central nervous system tissue from acute phase treated animals sampled at chronic time points and from animals given IGF-1 during the chronic phase revealed no enhancing effect on remyelination in comparison to vehicle-treated controls. Examination of oligodendrocyte progenitor populations also revealed no differences between IGF-1- and vehicle-treated groups. At the cytokine level, the immunomodulatory molecules TGF-β2 and TGF-β3 displayed significant decreases that may have contributed to the transient nature of the effect of IGF-1 on EAE. Together with evidence from previous studies, it appears doubtful that IGF-1 is a good candidate for treatment in multiple sclerosis, for which EAE serves as a major model.

Original languageEnglish (US)
Pages (from-to)933-943
Number of pages11
JournalAmerican Journal of Pathology
Volume157
Issue number3
StatePublished - 2000

Fingerprint

Demyelinating Diseases
Somatomedins
Myelin Sheath
Autoimmune Experimental Encephalomyelitis
Central Nervous System
Nerve Tissue
Oligodendroglia
Multiple Sclerosis
Regeneration
Cytokines
Population

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Insulin-like growth factor-1 fails to enhance central nervous system myelin repair during autoimmune demyelination. / Cannella, B.; Pitt, D.; Capello, E.; Raine, C. S.

In: American Journal of Pathology, Vol. 157, No. 3, 2000, p. 933-943.

Research output: Contribution to journalArticle

Cannella, B. ; Pitt, D. ; Capello, E. ; Raine, C. S. / Insulin-like growth factor-1 fails to enhance central nervous system myelin repair during autoimmune demyelination. In: American Journal of Pathology. 2000 ; Vol. 157, No. 3. pp. 933-943.
@article{f838ffea2edd4139afa10e8039864e2f,
title = "Insulin-like growth factor-1 fails to enhance central nervous system myelin repair during autoimmune demyelination",
abstract = "Previous studies have shown that insulin-like growth factor-1 (IGF-1) has beneficial effects, both clinically and histopathologically, on experimental autoimmune encephalomyelitis (EAE), although results vary depending on species and treatment regimen. The present study investigated whether IGF-1, delivered at different time points during the acute and chronic phases of adoptively transferred EAE in SJL mice, had the ability to affect or enhance myelin regeneration. Central nervous system tissue sampled at different stages of treatment was subjected to detailed neuropathological, immunocytochemical and molecular analysis. The results revealed some transient clinical amelioration and low level remyelination after IGF-1 administration during the acute phase of EAE. However, central nervous system tissue from acute phase treated animals sampled at chronic time points and from animals given IGF-1 during the chronic phase revealed no enhancing effect on remyelination in comparison to vehicle-treated controls. Examination of oligodendrocyte progenitor populations also revealed no differences between IGF-1- and vehicle-treated groups. At the cytokine level, the immunomodulatory molecules TGF-β2 and TGF-β3 displayed significant decreases that may have contributed to the transient nature of the effect of IGF-1 on EAE. Together with evidence from previous studies, it appears doubtful that IGF-1 is a good candidate for treatment in multiple sclerosis, for which EAE serves as a major model.",
author = "B. Cannella and D. Pitt and E. Capello and Raine, {C. S.}",
year = "2000",
language = "English (US)",
volume = "157",
pages = "933--943",
journal = "American Journal of Pathology",
issn = "0002-9440",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Insulin-like growth factor-1 fails to enhance central nervous system myelin repair during autoimmune demyelination

AU - Cannella, B.

AU - Pitt, D.

AU - Capello, E.

AU - Raine, C. S.

PY - 2000

Y1 - 2000

N2 - Previous studies have shown that insulin-like growth factor-1 (IGF-1) has beneficial effects, both clinically and histopathologically, on experimental autoimmune encephalomyelitis (EAE), although results vary depending on species and treatment regimen. The present study investigated whether IGF-1, delivered at different time points during the acute and chronic phases of adoptively transferred EAE in SJL mice, had the ability to affect or enhance myelin regeneration. Central nervous system tissue sampled at different stages of treatment was subjected to detailed neuropathological, immunocytochemical and molecular analysis. The results revealed some transient clinical amelioration and low level remyelination after IGF-1 administration during the acute phase of EAE. However, central nervous system tissue from acute phase treated animals sampled at chronic time points and from animals given IGF-1 during the chronic phase revealed no enhancing effect on remyelination in comparison to vehicle-treated controls. Examination of oligodendrocyte progenitor populations also revealed no differences between IGF-1- and vehicle-treated groups. At the cytokine level, the immunomodulatory molecules TGF-β2 and TGF-β3 displayed significant decreases that may have contributed to the transient nature of the effect of IGF-1 on EAE. Together with evidence from previous studies, it appears doubtful that IGF-1 is a good candidate for treatment in multiple sclerosis, for which EAE serves as a major model.

AB - Previous studies have shown that insulin-like growth factor-1 (IGF-1) has beneficial effects, both clinically and histopathologically, on experimental autoimmune encephalomyelitis (EAE), although results vary depending on species and treatment regimen. The present study investigated whether IGF-1, delivered at different time points during the acute and chronic phases of adoptively transferred EAE in SJL mice, had the ability to affect or enhance myelin regeneration. Central nervous system tissue sampled at different stages of treatment was subjected to detailed neuropathological, immunocytochemical and molecular analysis. The results revealed some transient clinical amelioration and low level remyelination after IGF-1 administration during the acute phase of EAE. However, central nervous system tissue from acute phase treated animals sampled at chronic time points and from animals given IGF-1 during the chronic phase revealed no enhancing effect on remyelination in comparison to vehicle-treated controls. Examination of oligodendrocyte progenitor populations also revealed no differences between IGF-1- and vehicle-treated groups. At the cytokine level, the immunomodulatory molecules TGF-β2 and TGF-β3 displayed significant decreases that may have contributed to the transient nature of the effect of IGF-1 on EAE. Together with evidence from previous studies, it appears doubtful that IGF-1 is a good candidate for treatment in multiple sclerosis, for which EAE serves as a major model.

UR - http://www.scopus.com/inward/record.url?scp=0034495084&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034495084&partnerID=8YFLogxK

M3 - Article

C2 - 10980132

AN - SCOPUS:0034495084

VL - 157

SP - 933

EP - 943

JO - American Journal of Pathology

JF - American Journal of Pathology

SN - 0002-9440

IS - 3

ER -